Form SD PARK OHIO HOLDINGS CORP
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
FORM SD
Specialized Disclosure Report
___________________
Park-Ohio Holdings Corp.
(Exact name of registrant as specified in its charter)
Ohio | 000-031341 | 34-1867219 | ||||||||||||
(State or other jurisdiction | (Commission | (IRS Employer | ||||||||||||
of incorporation or organization) | File Number) | Identification No.) | ||||||||||||
6065 Parkland Blvd. | ||||||||||||||
Cleveland, Ohio 44124 | ||||||||||||||
(Address of principal executive offices, including zip code) | ||||||||||||||
(Name and telephone number, including area code, of the person to contact in connection with this report.) | ||
Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
x | Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2025. | ||||
Section 1 – Conflict Minerals Disclosure
Item 1.01 Conflict Minerals Disclosure and Report
Conflict Minerals Disclosure
This Form SD of Park-Ohio Holdings Corp. (the “Company”) is filed pursuant to Rule 13p-1 under the Securities Exchange Act of 1934, as amended, for the reporting period from January 1, 2025 through December 31, 2025.
A copy of the Company’s Conflict Minerals Report is filed as Exhibit 1.02 to this Form SD and is in the investor relations section/SEC filings of the Company’s website at http://www.pkoh.com.
Item 1.02 Exhibit
A copy of the Company’s Conflict Minerals Report is filed as Exhibit 1.02 hereto.
Section 2 – Exhibits
Item 2.01 Exhibits
The following exhibit is filed as part of this Form SD.
Exhibit Number | Description of Exhibit | |||||||
1.02 | ||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
Park-Ohio Holdings Corp. | ||
(Registrant) | ||
/s/ Robert D. Vilsack | ||
Robert Vilsack | ||
General Counsel & Secretary | ||
June 1, 2026 | ||
(Date) | ||
EXHIBIT INDEX
Exhibit Number | Description of Exhibit | |||||||
1.02 | ||||||||
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma
- Monster Energy's Manel Kape Stops Kyoji Horiguchi at UFC Fight Night 279 in Las Vegas
- MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share